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ABSTRACT
Objective: Accelerated atherosclerosis associated
with an enhanced inflammatory state, which
characterizes ankylosing spondylitis (AS), is the
leading cause of increased cardiovascular risk.
The objective of this study was to assess carotid
intima-media thickness (CIMT) as a surrogate for
subclinical atherosclerosis in AS patients and its
possible correlation with disease-related clinical
parameters.
Methods: We performed a prospective study of
30 consecutive patients meeting modified New
York criteria for AS compared to 25 controls
matched for age and sex. Patients with traditional
CV risk factors were excluded. Disease-specific
measures and inflammatory measures (ESR, CRP,
TNF-a, IL-6 and IL-1) were determined. CIMT was
measured in the right common carotid artery
using high-resolution B-mode ultrasound.
Results: AS patients exhibited increased CIMT
compared to matched healthy controls
(0.62 ± 0.12 vs. 0.53 ± 0.09 mm). CIMT was
positively correlated with age, disease
duration, disease activity (BASDAI and ASDAS)
and the inflammatory measures ESR (r = 0.45,
P = 0.11) and TNF-a (r = 0.62, P\0.001). CIMT
did not correlate with the BMI, BASFI, IL-6, IL-1
or cholesterol levels.
Conclusions: This study shows increased CIMT
in AS patients without traditional
cardiovascular risk factors compared to healthy
controls. An increase in age, disease duration,
disease activity (BASDAI and ASDAS),
biomarkers of inflammation (ESR and CRP)
and TNF-a may predict the occurrence of





Patients with ankylosing spondylitis (AS) have
an increased cardiovascular morbidity and
mortality [1, 2]. Accelerated atherosclerosis
I. Verma  P. Krishan
Department of Pharmaceutical Sciences and Drug
Research, Punjabi University, Patiala, India
A. Syngle (&)
Cardio Rheuma and Healing Touch City Clinic,
Chandigarh and Rheumatologist Fortis Multi
Specialty Hospital, Mohali, India
e-mail: ashitsyngle@yahoo.com
Rheumatol Ther (2015) 2:173–182
DOI 10.1007/s40744-015-0017-8
caused by a systemic inflammatory response has
been reported to be an important risk factor for
increased cardiovascular risk for autoimmune
diseases such as rheumatoid arthritis (RA),
psoriatic arthritis (PsA) and systemic lupus
erythematosus (SLE) [3]. The risk of myocardial
infarction increases in younger patients and
those with more severe disease (defined by
disease activity) even after adjustment for
traditional cardiovascular risk factors
(hypertension, hyperlipidemia, diabetes,
smoking and body mass index) in AS patients
[4]. Among the various screening methods,
carotid intima-media thickness (CIMT)
according to high-resolution ultrasonography
has been established as a clinically useful index
for identifying early stage atherosclerosis
predicting future cardiovascular events [5].
In the present study, we assessed carotid
intima-media thickness in AS patients with
matched healthy controls who did not have
traditional cardiovascular risk factors. We also
studied the possible correlation between CIMT
and disease activity and disease ability indices.
METHODS
Study Subjects
This was a cross-sectional study in which 55
participants were recruited and divided into two
groups. Thirty AS patients (9 females and 21
males, aged 19–49 years) who fulfilled the 1984
modified New York diagnostic criteria for
diagnosising ankylosing spondylitis were
recruited [6] and 25 age- and sex-matched
healthy controls (7 females and 18 males, age
23–48 years) recruited from our clinic staff.
Detailed patient and healthy control
characteristics are depicted in Table 1. All
patients were on a combination of NSAIDs
(mostly etoricoxib or piroxicam) and a stable
dose of sulfasalazine 1–3 g/day for at least
3 months prior to study enrollment.
The study protocol was approved by the
Institutional Clinical Ethics Committee (ICEC),
and written informed consent was taken from
all the participants. The study subjects with a
history of hyperlipidemia [total cholesterol
[240 mg/dl, low-density lipoprotein
cholesterol (LDL) [160 mg/dl; prevalence of
dyslipidemia defined according to the National
Cholesterol Education Program Adult
Treatment Panel III (NCEP ATP III) criteria] [7],
diabetes, smokers and obesity (BMI[30),
coronary artery disease or patients on
antihypertensive treatment (blood pressure:
systolic[140 mmHg, diastolic[90 mmHg)
were excluded. Patients were also excluded if
they had a history of alcoholic liver disease,
renal insufficiency, stroke, thyroid disorder,
multiple sclerosis, human immunodeficiency
virus infection, psoriasis or inflammatory
bowel disease or psychiatric disorders. Patients
taking medication likely to affect endothelial
function (TNF-a inhibitors, steroids, beta
blockers, angiotensin-converting enzyme
inhibitor, angiotensin receptor blocker, statins
and aldosterone antagonist, peroxisome
proliferator-activated receptor). Patients were
also excluded if they had rheumatic disorders
other than ankylosing spondylitis.
Clinical and Biochemical Assessment
Patients underwent clinical evaluation at the
time of recruitment. Disease activities were
calculated and recorded using the Bath
Ankylosing Spondylitis Disease Activity Index
(BASDAI) [8] and Ankylosing Spondylitis
Disease Activity Score (ASDAS) including the
CRP [9]. The functional status of the patients in
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our study was evaluated with the Bath
Ankylosing Spondylitis Functional Index
(BASFI) [10]. Body mass index (BMI) was
calculated as the ratio of weight (kg) to height
(m) squared (kg/m2). Blood pressure was
recorded with a mercury column
sphygmomanometer.
Biochemical assessment including a
complete blood count, liver function tests,
renal function test, vitamin B12,
Table 1 Demographic, clinical and biochemical characteristics of the study subjects
Variable Ankylosing spondylitis Healthy controls P value
n 30 25 –
Age (years) 34.2 ± 8.7 36.9 ± 6.6 0.21
Gender: M/F (n) 21/9 18/7 –
BMI (kg/m2) 23.5 ± 3.0 22.6 ± 2.7 0.57
Smoking (n) 0 0 –
Systolic BP (mmHg) 121.5 ± 6.9 118.6 ± 6.5 0.13
Diastolic BP (mmHg) 83.4 ± 6.0 80.9 ± 7.9 0.19
Disease duration (years) 8.7 ± 5.8 – –
HbA1c (%) 4.8 ± 0.6 4.06 ± 0.7 0.23
Serum creatinine (lmol/l) 0.81 ± 0.08 0.84 ± 0.1 0.21
Total cholesterol (mg/dl) 181.8 ± 17.0 179.92 ± 12.5 0.29
HDL cholesterol (mg/dl) 44.6 ± 5.2 49.2 ± 4.6 0.09
LDL cholesterol (mg/dl) 103.7 ± 17.9 99.4 ± 19.5 0.12
Triglycerides (mg/dl) 120.2 ± 17.1 125.4 ± 26.2 0.16
ESR (mm 1st h) 29.03 ± 10.29 16.64 ± 4.53 \0.001*
CRP (mg/dl) 14.92 ± 12.71 3.78 ± 1.05 \0.001*
BASDAI 4.89 ± 0.61 – –
ASDAS 2.86 ± 0.71 – –
BASFI 2.73 ± 1.30 – –
CIMT (mm) 0.62 ± 0.12 0.53 ± 0.09 0.006*
TNF-a (pg/ml) 9.92 ± 3.74 3.26 ± 1.13 \0.001*
IL-6 (pg/ml) 18.22 ± 8.44 4.0 ± 0.80 0.001*
IL-1 (pg/ml) 177.3 ± 88.6 90.0 ± 18.9 \0.001*
Values are mean ± SD
BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, ESR erythrocyte sedimentation rate,
CRP C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS Ankylosing Spondylitis
Disease Activity Score, BASFI Bath Ankylosing Spondylitis Functional Index, CIMT carotid intima-media thickness,
TNF-a tumor necrosis factor-a, IL-6 interleukin-6, IL-1 interleukin-1
* P \0.05
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thyroid-stimulating hormone, blood sugar and
HbA1c were determined using standard
commercial kits and urine analysis to detect
proteinuria, hematuria and cellular casts.
Inflammatory markers, i.e., the erythrocyte
sedimentation rate (ESR), were measured using
the Westergren method and C-reactive protein
(CRP) level using standard commercial kits.
Inflammatory cytokines, tumor necrosis factor
(TNF)-a, interleukin (IL)-6 and IL-1 values were
also assessed in all subjects by the ELISA
method. All patients underwent clinical and
biochemical assessment at the time of
recruitment. Clinical, biochemical and CIMT
assessments were carried out on the same day of
recruitment after overnight fasting.
Assessment of Carotid Intima-Media
Thickness
All subjects were examined using a
high-resolution Doppler ultrasound (HD 11 XE
ultrasound machine, Philips Medical System)
using a 13–5-MHz linear array transducer in the
supine position. The CCA intima-media
thickness (IMT) was defined as the average of
the maximum IMT of the near and far wall
measurements in the distal CCA (1 cm proximal
to the carotid bulb). Intima-media thickness
was measured at three points on the far walls of
both the left and right common carotid arteries
(CCA). The three locations were then averaged
to produce the mean IMT for each side. All
images of the carotid arteries were recorded on
the hard disk of the ultrasound system for
subsequent analysis and evaluated by a
well-experienced radiologist who was blinded
to the clinical characteristics of the participants
[11]. The subjects had fasted overnight, and
they were studied in the morning between 9
and 11 a.m. The intra- and interobserver
variability had coefficient of variations is
2.11–2.45%, respectively, for measurements of
CIMT.
Statistical Analysis
Continuous data are expressed as the
mean ± standard deviation (SD). Patients and
healthy control subjects were compared using
unpaired Student’s t test for continuous
variables and the chi-squared test for
categorical variables. Pearson correlation
coefficients were calculated for AS patients to
study the relationship between CIMT and
clinical and biochemical disease variables.
Two-sided P values of less than 0.05 were
considered statistically significant. The
statistical analysis was carried out using
Sigmastat 5.5 for Windows 7.
RESULTS
The demographics, clinical and biochemical
characteristics of study subjects are
summarized in Table 1. There were no
significant differences in age, sex and mean
BMI values between AS patients and healthy
controls. All study subjects were free from any
traditional cardiovascular risk factors and
cardiovascular disorders. The clinical index of
disease activity (BASDAI and ASDAS) was
4.89 ± 0.61 and 2.86 ± 0.71, respectively, and
the functional status (BASFI) 2.73 ± 1.30 at the
time of the study (Table 1). There were
significant differences in the ESR and CRP
levels between the AS patients and controls
(both P\0.001). Total cholesterol, HDL
cholesterol, LDL cholesterol, triglycerides and
HbA1c levels were similar in both groups
(P[0.005). The mean serum level of
proinflammatory cytokines, i.e., TNF-a, IL-6
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and IL-1, in AS patients was higher than that in
healthy controls (P\0.001, 0.001 and\0.001,
respectively, Table 1). Compared to healthy
controls, AS patients exhibited increased CIMT
(0.62 ± 0.12 vs. 0.53 ± 0.09 mm, P = 0.006)
(Fig. 1).
Correlation Analysis of CIMT with Clinical
Characteristics and Biomarkers
of Inflammation in AS Patients
CIMT was positively correlated with age, disease
duration, disease activity measures (BASDAI and
ASDAS) and inflammatory markers such as ESR,
CRP and TNF-a (Table 2). No significant
correlation was observed between CIMT and
BMI, BASFI, IL-6 and IL-1 (Table 2). Also no
significant correlation was observed between
CIMT and total cholesterol, HDL, LDL and TG
(Table 2).
DISCUSSION
Results of the present study demonstrate that AS
patients without any known traditional
cardiovascular risk factors (hypertension,
hypercholesterolemia, diabetes, obesity and
smoking) and CV disorders have a high
prevalence of atherosclerosis exhibited by
increased carotid intima-media thickness
compared to matched controls. Age, disease
duration, high disease activity and
inflammatory response expressed by the ESR,
CRP and TNF-a level emerged as the predictors
of subclinical atherosclerotic disease manifested
by the increased CIMT using high-resolution
B-mode ultrasound. This is the first study to
report a significant correlation between TNF-a
(inflammatory cytokines involved in the
pathogenesis of AS) and CIMT in AS. These
results may help to explain the increased
cardiovascular morbidity and mortality
observed in AS patients.
AS and another autoimmune rheumatic
diseases such as RA and PsA have been known
to be associated with accelerated atherogenesis
Fig. 1 Comparison between mean carotid intima-media
thickness (CIMT) of both patients and controls
Table 2 Correlations analysis of CIMT with clinical
characteristics and biomarkers of inﬂammation
Variables CIMT















Values were calculated using Pearson’s correlation
coefﬁcient
* P\0.05
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and increased cardiovascular morbidity and
mortality [12–14]. Assessment of CIMT is an
accepted and established marker to detect early
atherosclerosis in asymptomatic subjects; it is
considered a strong biomarker of cardiovascular
risk [15] and has been extensively used as a
surrogate end point in primary intervention
studies of cardiovascular risk reduction [16].
The prevalence of increased subclinical
atherosclerosis has been studied previously in
AS through the assessment of CIMT and FMD,
but the partial exclusion of traditional
cardiovascular risk factors, cardiovascular
events or concomitant medications has led to
ambiguous results [17–24]. Hence, we excluded
AS patients with traditional cardiovascular risk
factors, manifested cardiovascular disease or AS
patients on medications (TNF-a inhibitors,
steroids, beta blockers, angiotensin-converting
enzyme inhibitor, angiotensin receptor blocker,
statins, aldosterone antagonist and peroxisome
proliferator-activated receptor) likely to
influence atherosclerosis.
In the present study, we demonstrated an
increased CIMT in AS patients compared to
matched controls. Other studies have also
shown a similar increase in CIMT in AS
patients in the absence or presence of
cardiovascular risk factors. The mean CIMT
(0.62 mm) discovered in the present study is
comparable to that in reported studies [18, 21,
23]. However, Choe et al. did not find a
statistically significant difference between 28
young AS patients with low disease activity and
short disease duration (5.0 years) compared to
27 matched healthy controls [25]. This is not
surprising given the result of the present study.
In a 2008 study by Mathieu et al. that
encompassed a series of 60 AS patients with
long-standing disease (mean, 11 year) compared
to 60 controls, no differences in the CIMT were
observed. Almost 50% of the participating AS
patients in the Mathieu et al. study had been
treated with TNF inhibitors [26].
To date, any relationship among AS
variables, inflammatory cytokines and
atherosclerosis is merely speculative. On
univariate analysis, CIMT was positively
correlated with patient age and disease
duration, suggesting that patient age and
disease duration are associated with increased
risk of developing atherosclerosis in AS. Other
authors have also reported this association
between CIMT and age and disease duration
[17, 19, 20, 22–24]. CIMT was positively
correlated with increased disease activity,
measured using BASDAI scores and ASDAS, in
support of the hypothesis that disease activity
may influence atherosclerosis in AS patients. A
similar, result was confirmed by Hamdi et al.
[24], but different findings have been reported
by other authors [17, 19, 20, 22, 23].
In addition, we also found that increased
CIMT was significantly correlated with
inflammatory measures (ESR and CRP),
suggesting that systemic inflammation in AS
may accelerate the atherosclerotic process. The
correlation between CIMT and ESR has been
demonstrated by other authors as well [17, 21,
23, 24], while others did not find a significant
correlation [19, 20, 22]. An elevated CRP, one of
the best surrogate markers of systemic
inflammation, is known to promote
endothelial cell activation and atherosclerotic
processes [27, 28]. CRP has been a particularly
consistent predictor of increased risk for
atherosclerosis in the general population. Our
study is consistent with this observation; higher
CRP levels were correlated with increased CIMT
in AS. This finding is also supported by Hamdi
and coworkers, who reported that CIMT was
correlated with the CRP level [24]. The mean
CRP (18.9 ± 22.9) reported by Hamid et al. was
comparable to the results of our study. This
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suggests that higher levels of CRP may
contribute to accelerated atherosclerosis in AS.
In the general population, epidemiologic
studies have shown that the CRP level is an
independent predictor of CV events [29].
However, no correlation has been observed
between CIMT and CRP in AS studies with
relatively lower CRP levels [20–26].
We also found that increased CIMT was
significantly correlated with TNF-a, suggesting
a contribution to progression of increased CIMT
in AS. The correlation between CIMT and IL-1
was not significantly correlated in the present
study, but it showed a trend toward a positive
correlation (P = 0.06). In our study, no
correlation was observed between CIMT and
IL-6. TNF-a is an important proinflammatory
cytokine involved in the pathogenesis of AS and
a potential risk factor of cardiovascular risk.
High levels of circulating cytokines TNF-a, IL-6
and IL-1 are in a position to alter the function of
distant tissues, including adipose, skeletal
muscle, liver and vascular endothelium, to
generate a spectrum of proatherogenic changes
that includes insulin resistance, a characteristic
dyslipidemia, prothrombotic effects,
prooxidative stress and endothelial
dysfunction [30]. Previously, proinflammatory
cytokines (TNF-a, IL-6 and IL-1) had not been
measured in any of these studies [17, 20–24, 26].
However, Choe et al. estimated the serum level
of IL-6 and TNF-a and demonstrated that the
serum levels of IL-6 in AS patients was
significantly different compared to controls,
but not in serum levels of TNF- a. Choe et al.
did not find any correlation between CIMT and
the serum level of IL-6 and TNF-a in AS. This
might be due to the shorter disease duration
and low disease activity in the patients included
in the study [25]. To the best of our knowledge,
the impact of TNF-a blockade on CIMT has not
been investigated in AS. However, TNF-a
blockade has been shown to improve
endothelial dysfunction in AS [31, 32]. A study
by Porto et al. in 287 consecutive RA patients
demonstrated TNF-a blockade is associated with
CIMT reduction, probably by lowering
inflammation [33]. Another recent study also
demonstrated that TNF- a blockade significantly
reduced CIMT as compared to DMARDs in PsA
patients [34].
In the present study, we did not find a
significant correlation of CMIT with BASFI, BMI
and cholesterol levels. BASFI is an index of
functionality. Functional disability may occur
over a relatively short period of time depending
on disease severity. Moreover, BASFI can vary
day to day or week to week. Hence, it is not
surprising that BASFI did not correlate with
CIMT. In keeping with our results, many
investigators have not found a correlation
between CIMT and BASFI [17, 21–23, 25]. In
our study, BMI and total cholesterol, HDL, LDL
cholesterol and triglycerides were similar in
both groups, as reported in some other studies
[22, 23, 25]. Thus, the atherogenic lipid profile
cannot completely explain the higher CIMT
levels in patients when compared to healthy
controls.
Study strength and limitations: This study
design had several strengths, notably analyses
of a well-characterized patient population and
measurement of many inflammatory mediators
reported to be associated with accelerated
atherosclerosis. A potential limitation of the
current study was the small sample size, and the
potential confounding effect of synthetic
DMARDs (sulfasalazine) on CIMT could not be
accounted for in this study. However, this study
has identified risk factors for the development
of atherosclerosis in AS. These risk factors can
serve as potential therapeutic targets to prevent
atherosclerosis and hence CV disease in AS
patients.
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CONCLUSION
The present study demonstrates that patients
with ankylosing spondylitis without traditional
cardiovascular risk factors have increased
carotid intima-media thickness compared to
matched healthy controls. Age, longer disease
duration, increased disease activity (BASDAI
and ASDAS), biomarkers of inflammation (ESR
and CRP) and proinflammatory cytokines
(TNF-a) are incriminating factors for CIMT
surrogate markers of accelerated atherosclerosis
in AS. Further studies with larger sample sizes of
patients are required to investigate the risk
factors and consequences of subclinical
atherosclerosis in AS.
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